Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 106, Issue 5, Pages 758-763Publisher
WILEY
DOI: 10.1002/jcb.22048
Keywords
SYNTHETIC LETHALITY; HELICASE; CANCER THERAPY; DNA REPAIR; ANTI-CANCER DRUG
Categories
Funding
- NIH
- National Institute on Aging
Ask authors/readers for more resources
Designing strategies for anti-cancer therapy have posed a significant challenge. One approach has been to inhibit specific DNA repair proteins and their respective pathways to enhance chemotherapy and radiation therapy used to treat cancer patients. Synthetic lethality represents an approach that exploits pre-existing DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated repair deficiency. Since helicases play critical roles in the DNA damage response and DNA repair, particularly in actively dividing and replicating cells, it is proposed that the identification and characterization of synthetic lethal relationships of DNA helicases will be of value in developing improved anti-cancer treatment strategies. In this review, we discuss this hypothesis and current evidence for synthetic lethal interactions of eukaryotic DNA helicases in model systems. J. Cell. Biochem. 106: 758-763, 2009. Published 2009 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available